Genomma Lab Internacional SAB de CV (GNMLF) recently announced a dividend of $0.2 per share, payable on 2023-12-27, with the ex-dividend date set for 2023-12-22. As investors look forward to this ...

This article first appeared on GuruFocus. Genomma Lab Internacional SAB de CV (MEX:LABB) is set to release its Q3 2025 earnings on Oct 22, 2025. The consensus estimate for Q3 2025 revenue is $4.92 ...

(2) EBITDA defined as operating income before depreciation and amortization Net Sales: Like-for-like sales declined -3.9%, reflecting weak consumption in Mexico and disruptions in the U.S. Hispanic ...

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its First Quarter 2025 Earnings Results on Wednesday, April 30, 2025, after ...

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter of 2025. All figures included herein are stated in nominal ...

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and ...

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a ...

Like-for-like ("LFL") sales: when adjusted into constant currency and excluding the hyperinflationary subsidiary, sales increased by 9.7% reflecting a double-digit increase in six out of nine core ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an increasing international ...